Interestingly, TET2, an enzyme that catalyzes DNA demethylation, is a tumor suppressor in prostate cancer and is frequently mutated, with loss of TET2 expression associated with cancer progression and reduced patient survival (69, 88). This evidence concerns the gene TET2 and cancer.